10 For 10: Impact Across 10 Policy Areas in 10 Years

Since its establishment in 2009, the USC Schaeffer Center has spurred evidence-based research and analysis informing lawmakers, government agencies and the private sector on today’s pressing health policy issues. Schaeffer Center work is published in academic journals, white paper series and issue briefs, and Center experts are frequently called upon to provide advisement to policymakers, public testimony on salient issues and comment in the media. Committed to disseminating findings to a wide audience, the Center holds conferences and seminars in Los Angeles, Washington, D.C., and other cities, promoting dialogue and innovative approaches to the healthcare challenges facing the nation.

  1. The Schaeffer Center is INVESTING IN AMERICA’S FUTURE HEALTH using findings from the Future Elderly Model (FEM) – our health policy simulation that has been cited by the CBO, Social Security, and the President’s Council of Economic Advisors – to predict consequences of income disparities, quantify the value of new medical technologies, and assess the societal benefits of disease prevention. Experts, like Nobel Laureate James Heckman, use the FEM to predict health outcomes across the lifespan from the value of early childhood education to delayed onset of Alzheimer’s disease.
  2. When the White House, lawmakers, CMS, CBO and others needed rigorous analysis and evaluation, Schaeffer experts provided over 68 pivotal outputs that were INFORMING THE ACA DEBATE IN REAL TIME.
  3. MAKING MEDICARE WORK BETTER is a Schaeffer priority, including Nobel Laureate Daniel McFadden’s findings on Medicare Part D benefit design presented to CMS, HHS, and other federal and state agencies.
  4. Schaeffer’s expansive work FOSTERING BETTER PHARMACEUTICAL REGULATION – including outputs on the pharmaceutical supply chain, Medicaid best price rule, copayment coupons, clawbacks, and global burden of innovation – is used by lawmakers and agencies, including the White House, Senate, FTC, CMS and others. Our innovative pricing models aim to increase access and lower consumer prices.
  5. As consolidation continues in health care, Schaeffer experts are IMPROVING THE PERFORMANCE OF HEALTH CARE MARKETS by examining the impact of these trends on competition and premiums. Our work has been cited by the CBO, and experts have testified in the U.S. Senate and California State Senate.
  6. The CDC cites our research CURBING INAPPROPRIATE PRESCRIBING as a “best practice,” and a Schaeffer-led study found that simple, inexpensive behavioral nudges reduced physician overprescribing. States, the NIH and private plans are looking at this approach. These innovative behavioral nudges are now being studied to fight the opioid epidemic.
  7. Schaeffer work DEMONSTRATING HOSPITAL AND HEALTH SYSTEM PRODUCTIVITY AND GROWTH looks at the effects of quality of care and severity of patient illness on these measures. Our work was foundational to a recent bipartisan bill addressing the issue of surprise medical bills under consideration in the Senate.
  8. Working with the OECD and other nations, Schaeffer experts are PROMOTING HEALTHIER COMMUNITIES GLOBALLY by effectively modeling future trends and bringing these findings into programs and policies. Our work in India played a pivotal role in the Indian government’s decision to provide insurance to 65 million of its citizens.
  9. Schaeffer experts are EXPANDING ACCESS TO THERAPIES FOR INFECTIOUS DISEASES. Our work was instrumental in assessing the value of early treatments for HIV/AIDS, and more recently the CDC, HHS and state policy makers have reviewed our unique payment model that expands access to hepatitis B therapies and hepatitis C cures.
  10. The Schaeffer Center is REDEFINING VALUE IN CANCER CARE with a series of research papers on new approaches to serious illness. Schaeffer experts provide insights to public and private-sector leaders on new payment models that increase access to innovative – and expensive – therapies.